Truist cuts Boston Scientific stock price target on Watchman concerns

Truist cut Boston Scientific’s price target to $90 from $92 while keeping a Buy rating, citing slower Watchman momentum and decelerating trends in both Watchman and electrophysiology after Q4 2025. The firm expects Q1 2026 revenue and EPS to come in within guidance, but projects Watchman growth of 18% year over year versus consensus near 22% and sees potential pressure on 2026 organic revenue guidance. Despite the caution, the article notes other analysts remain constructive, with UBS at $105, RBC at $115, and Piper Sandler overweight following CHAMPION-AF trial results.

Analysis

The key market issue is not the near-term earnings print; it is whether Watchman’s growth deceleration becomes a narrative reset for the entire structural heart franchise. When a category leader misses on a flagship implant, the second-order effect is typically not just lower revenue—it raises hurdle rates across adjacent electrophysiology and LAA adoption, because physicians and hospital buyers tend to defer conversions when the lead product’s momentum looks unstable. That creates a self-reinforcing “pause” in procedure volumes that can last 1-2 quarters even if the underlying clinical data remain intact.

The market appears to be pricing a modest de-rating, but the asymmetry is still unfavorable if guidance comes down again in the upcoming report. A cut to organic growth from low-double-digits toward ~8% would matter more than the exact Watchman number because it would signal that management’s prior growth algorithm is no longer reliable; that usually compresses multiple more than any single product miss. The main offset is that the franchise remains underappreciated on balance-sheet quality and breadth, so if Q1 is merely a reset rather than a true demand break, the stock can stabilize quickly once sell-side models finish coming down.

The contrarian angle is that the Street may be over-anchored to trial optics and underestimating how much of the softness is timing rather than share loss. If March trial readthroughs improve adoption economics, the current selloff could prove to be a multi-month mispricing rather than a structural impairment. The biggest tail risk is that management uses guidance to acknowledge a broader slowdown across cardiovascular rather than just Watchman, which would turn this from a product-specific issue into a portfolio-wide confidence event.

Key Decisions for Investors

• Avoid buying BSX ahead of Q1; wait for the print and guidance reset. If management trims organic growth to ~8% and confirms Watchman deceleration, the stock can likely trade another 8-12% lower before value buyers step in.
• For accounts already long BSX, consider a short-dated collar into earnings: sell upside calls against core holdings and finance downside protection for the next 2-4 weeks. This is the cleanest way to stay invested while neutralizing event risk.
• If the post-print selloff is >10% and the company only confirms a timing issue, initiate a tactical long in BSX with a 3-6 month horizon. Use a 2:1 risk/reward framework: downside capped by quality and valuation support, upside driven by model stabilization and multiple repair.
• Relative-value idea: long BSX / short a higher-multiple medtech name with more earnings risk over the next quarter. The trade works if investors punish guidance compression more than they reward trial-driven optionality.
• Set a catalyst alert for the March trial readthrough. If adoption data improve, add to BSX on confirmation; if not, treat any bounce as an exit opportunity rather than a durable rerating.